Kymera CFO trades shares, receives equity awards

Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of share sales and new equity awards.

Rhea-AI Filing Summary

Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of share sales and new equity awards. Across several open-market transactions on March 2 and March 4, 2026, he sold a total of 12,471 shares of common stock at weighted average prices between roughly $83.9965 and $89.6574 per share, leaving him with 232,588 shares held directly.

On March 2, 2026, he also received 17,650 restricted stock units, which vest in four equal annual installments after that date, and a stock option covering 35,300 shares, vesting in 48 equal monthly installments after the same date. Some of the sales were required solely to cover tax withholding obligations tied to RSU vesting and were executed automatically.

Insider Trade Summary

Net Seller: 12,471 shares

Net Sell 9 txns

Insider Jacobs Bruce N.

Role Chief Financial Officer

Sold 12,471 shs ($1.09M)

Type	Security	Shares	Price	Value
Sale	Common Stock	492	$83.9965	$41K
Sale	Common Stock	2,519	$85.0364	$214K
Sale	Common Stock	1,437	$85.7807	$123K
Sale	Common Stock	447	$86.6247	$39K
Grant/Award	Stock Option (Right to Buy)	35,300	$0.00	$0.00
Grant/Award	Common Stock	17,650	$0.00	$0.00
Sale	Common Stock	2,039	$87.7509	$179K
Sale	Common Stock	1,424	$88.5004	$126K
Sale	Common Stock	4,113	$89.6574	$369K

Holdings After Transaction: Stock Option (Right to Buy) — 35,300 contracts (Direct); Common Stock — 232,588 shares (Direct)

Footnotes (10)

1. F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.
2. F2. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. F10. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kymera (KYMR) CFO Bruce Jacobs report in this Form 4?

Kymera’s CFO Bruce N. Jacobs reported a combination of equity awards and share sales. He received new restricted stock units and stock options, and sold several blocks of common stock while retaining a substantial direct holding after these transactions.

How many Kymera (KYMR) shares did the CFO sell in these transactions?

Bruce Jacobs sold 12,471 shares of Kymera common stock in multiple open-market transactions. These sales occurred on March 2 and March 4, 2026, at various weighted average prices in the mid-to-high $80s per share across several separate trades.

What new equity awards did the Kymera (KYMR) CFO receive?

He received 17,650 restricted stock units and a stock option for 35,300 shares. The RSUs vest in four equal annual installments after March 2, 2026, and the stock option vests in 48 equal monthly installments following that same grant date.

Were any Kymera (KYMR) CFO share sales related to tax withholding?

Yes. Some reported sales represent shares that had to be sold to cover tax withholding obligations triggered by RSU vesting. The filing notes these particular sales were automatic and not made at the discretion of Bruce Jacobs personally.

How many Kymera (KYMR) shares does the CFO hold after these trades?

After completing the reported transactions, Bruce Jacobs directly holds 232,588 shares of Kymera common stock. This figure reflects his position following both the new equity awards and the various open-market and tax-related sales described in the Form 4.

What are the vesting terms for the Kymera (KYMR) CFO’s new stock option?

The new stock option for 35,300 Kymera shares vests in 48 equal monthly installments following March 2, 2026. Each monthly vesting tranche is contingent on Bruce Jacobs remaining employed with the company through the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobs Bruce N.

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		17,650(1)	A	$0	245,059	D
Common Stock	03/02/2026		S(2)		2,039	D	$87.7509(3)	243,020	D
Common Stock	03/02/2026		S(2)		1,424	D	$88.5004(4)	241,596	D
Common Stock	03/02/2026		S(2)		4,113	D	$89.6574(5)	237,483	D
Common Stock	03/04/2026		S(2)		492	D	$83.9965(6)	236,991	D
Common Stock	03/04/2026		S(2)		2,519	D	$85.0364(7)	234,472	D
Common Stock	03/04/2026		S(2)		1,437	D	$85.7807(8)	233,035	D
Common Stock	03/04/2026		S(2)		447	D	$86.6247(9)	232,588	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$90.1	03/02/2026		A		35,300		(10)	03/01/2036	Common Stock	35,300	$0	35,300	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

2. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date.

	/s/ Bruce N. Jacobs	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.